

Global Genetic COPD Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G3D633C43962EN.html>

Date: December 2024

Pages: 170

Price: US\$ 2,800.00 (Single User License)

ID: G3D633C43962EN

Abstracts

Report Overview

Genetic Chronic Obstructive Pulmonary Disease (COPD) refers to a hereditary form of COPD caused by genetic mutations. This subset of COPD is characterized by airflow limitation and respiratory symptoms. Genetic COPD is a niche segment within the broader COPD market, with a distinct focus on understanding the genetic predispositions and mutations that contribute to the development of the disease.

In 2023, the market size for Genetic COPD was estimated at approximately USD 45 million. The projected Compound Annual Growth Rate (CAGR) for the period 2024-2032 stands at 7.5%. This growth is primarily driven by increasing awareness about genetic factors influencing COPD, advancements in genetic testing technologies, and the rising prevalence of COPD globally.

One of the key growth drivers in the Genetic COPD market is the growing emphasis on personalized medicine and precision healthcare. As healthcare providers and pharmaceutical companies increasingly recognize the importance of genetic factors in disease management, the demand for genetic testing services and targeted therapies for Genetic COPD is expected to rise significantly.

Furthermore, the rise in research and development activities focused on understanding the genetic mechanisms underlying COPD is fueling market growth. With advancements in genetic sequencing technologies and bioinformatics, researchers can now identify specific genetic mutations associated with COPD, paving the way for the development of novel treatment approaches tailored to individual patients.

In terms of market trends, there is a noticeable shift towards integrating genetic testing into routine clinical practice for COPD diagnosis and management. Genetic biomarker identification and validation are becoming integral parts of disease stratification and treatment selection, enabling healthcare providers to deliver more personalized and effective care to patients with Genetic COPD.

Moreover, the increasing adoption of telemedicine and digital health solutions is facilitating broader access to genetic testing services for patients with Genetic COPD. Remote genetic counseling and testing services are overcoming traditional barriers to access, particularly in underserved regions, thereby expanding the market reach and driving market growth.

Regional market distribution in Genetic COPD is influenced by factors such as the prevalence of COPD, availability of healthcare infrastructure, and research investments. Leading markets for Genetic COPD include North America and Europe, where robust healthcare systems, research funding, and a high prevalence of COPD contribute to market dominance. In these regions, key market dynamics revolve around collaborations between academic institutions, healthcare providers, and pharmaceutical companies to advance genetic research in COPD.

Despite the promising growth prospects, the Genetic COPD market faces challenges such as regulatory complexities surrounding genetic testing, data privacy concerns, and the need for standardization in genetic testing protocols. Addressing these challenges will be crucial for sustaining market growth and ensuring the effective integration of genetic insights into COPD management strategies.

This report provides a deep insight into the global Genetic COPD market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Genetic COPD Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Genetic COPD market in any manner.

Global Genetic COPD Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Pfizer

Baxter

AstraZeneca

Grifols

Teva Pharmaceutical Industries

Boehringer Ingelheim

Kamada Ltd

GlaxoSmithKline

CSL Behring

Takeda

LFB Biomedicaments

Abeona Therapeutics

Biogen

Vertex Pharmaceuticals

Baxalta

Arrowhead Research Corporation

ProBioGen

Chiesi Pharmaceuticals

Kedrion Group

ProMetic Life Sciences

Market Segmentation (by Type)

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Other

Market Segmentation (by Application)

Hospitals

Specialty Clinics

Pharmacies

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Genetic COPD Market

Overview of the regional outlook of the Genetic COPD Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your

competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Genetic COPD Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail,

including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Genetic COPD

1.2 Key Market Segments

1.2.1 Genetic COPD Segment by Type

1.2.2 Genetic COPD Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 GENETIC COPD MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Genetic COPD Market Size (M USD) Estimates and Forecasts (2019-2032)

2.1.2 Global Genetic COPD Sales Estimates and Forecasts (2019-2032)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

2.4 Macroeconomic Analysis

3 GENETIC COPD MARKET COMPETITIVE LANDSCAPE

3.1 Global Genetic COPD Sales by Manufacturers (2019-2024)

3.2 Global Genetic COPD Revenue Market Share by Manufacturers (2019-2024)

3.3 Genetic COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Genetic COPD Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Genetic COPD Sales Sites, Area Served, Product Type

3.6 Genetic COPD Market Competitive Situation and Trends

3.6.1 Genetic COPD Market Concentration Rate

3.6.2 Global 5 and 10 Largest Genetic COPD Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 GENETIC COPD INDUSTRY CHAIN ANALYSIS

- 4.1 Genetic COPD Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF GENETIC COPD MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 GENETIC COPD MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Genetic COPD Sales Market Share by Type (2019-2024)
- 6.3 Global Genetic COPD Market Size Market Share by Type (2019-2024)
- 6.4 Global Genetic COPD Price by Type (2019-2024)

7 GENETIC COPD MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Genetic COPD Market Sales by Application (2019-2024)
- 7.3 Global Genetic COPD Market Size (M USD) by Application (2019-2024)
- 7.4 Global Genetic COPD Sales Growth Rate by Application (2019-2024)

8 GENETIC COPD MARKET SALES BY REGION

- 8.1 Global Genetic COPD Sales by Region
 - 8.1.1 Global Genetic COPD Sales by Region
 - 8.1.2 Global Genetic COPD Sales Market Share by Region
- 8.2 Global Genetic COPD Market Size by Region
 - 8.2.1 Global Genetic COPD Market Size by Region

8.2.2 Global Genetic COPD Market Size Market Share by Region

8.3 North America

8.3.1 North America Genetic COPD Sales by Country

8.3.2 North America Genetic COPD Market Size by Country

8.3.3 U.S. Market Overview

8.3.4 Canada Market Overview

8.3.5 Mexico Market Overview

8.4 Europe

8.4.1 Europe Genetic COPD Sales by Country

8.4.2 Europe Genetic COPD Market Size by Country

8.4.3 Germany Market Overview

8.4.4 France Market Overview

8.4.5 U.K. Market Overview

8.4.6 Italy Market Overview

8.4.7 Russia Market Overview

8.5 Asia Pacific

8.5.1 Asia Pacific Genetic COPD Sales by Region

8.5.2 China

8.5.3 Japan

8.5.4 South Korea

8.5.5 India

8.5.6 Southeast Asia

8.6 Asia Pacific

8.6.1 Asia Pacific Genetic COPD Market Size by Region

8.6.2 Asia Pacific Genetic COPD Market Size by Region

8.6.3 China

8.6.4 Japan

8.6.5 South Korea

8.6.6 India

8.6.7 Southeast Asia

8.7 South America

8.7.1 South America Genetic COPD Sales by Country

8.7.2 South America Genetic COPD Market Size by Country

8.7.3 Brazil

8.7.4 Argentina

8.7.5 Columbia

8.8 Middle East and Africa

8.8.1 Middle East and Africa Genetic COPD Sales by Region

8.8.2 Middle East and Africa Genetic COPD Market Size by Region

8.8.3 Saudi Arabia

8.8.4 UAE

8.8.5 Egypt

8.8.6 Nigeria

8.8.7 South Africa

9 GENETIC COPD MARKET PRODUCTION BY REGION

9.1 Global Production of Genetic COPD by Region (2019-2024)

9.2 Global Genetic COPD Revenue Market Share by Region (2019-2024)

9.3 Global Genetic COPD Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Genetic COPD Production

9.4.1 North America Genetic COPD Production Growth Rate (2019-2024)

9.4.2 North America Genetic COPD Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Genetic COPD Production

9.5.1 Europe Genetic COPD Production Growth Rate (2019-2024)

9.5.2 Europe Genetic COPD Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Genetic COPD Production (2019-2024)

9.6.1 Japan Genetic COPD Production Growth Rate (2019-2024)

9.6.2 Japan Genetic COPD Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Genetic COPD Production (2019-2024)

9.7.1 China Genetic COPD Production Growth Rate (2019-2024)

9.7.2 China Genetic COPD Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 Pfizer

10.1.1 Pfizer Genetic COPD Basic Information

10.1.2 Pfizer Genetic COPD Product Overview

10.1.3 Pfizer Genetic COPD Product Market Performance

10.1.4 Pfizer Business Overview

10.1.5 Pfizer Genetic COPD SWOT Analysis

10.1.6 Pfizer Recent Developments

10.2 Baxter

10.2.1 Baxter Genetic COPD Basic Information

10.2.2 Baxter Genetic COPD Product Overview

- 10.2.3 Baxter Genetic COPD Product Market Performance
- 10.2.4 Baxter Business Overview
- 10.2.5 Baxter Genetic COPD SWOT Analysis
- 10.2.6 Baxter Recent Developments
- 10.3 AstraZeneca
 - 10.3.1 AstraZeneca Genetic COPD Basic Information
 - 10.3.2 AstraZeneca Genetic COPD Product Overview
 - 10.3.3 AstraZeneca Genetic COPD Product Market Performance
 - 10.3.4 AstraZeneca Genetic COPD SWOT Analysis
 - 10.3.5 AstraZeneca Business Overview
 - 10.3.6 AstraZeneca Recent Developments
- 10.4 Grifols
 - 10.4.1 Grifols Genetic COPD Basic Information
 - 10.4.2 Grifols Genetic COPD Product Overview
 - 10.4.3 Grifols Genetic COPD Product Market Performance
 - 10.4.4 Grifols Business Overview
 - 10.4.5 Grifols Recent Developments
- 10.5 Teva Pharmaceutical Industries
 - 10.5.1 Teva Pharmaceutical Industries Genetic COPD Basic Information
 - 10.5.2 Teva Pharmaceutical Industries Genetic COPD Product Overview
 - 10.5.3 Teva Pharmaceutical Industries Genetic COPD Product Market Performance
 - 10.5.4 Teva Pharmaceutical Industries Business Overview
 - 10.5.5 Teva Pharmaceutical Industries Recent Developments
- 10.6 Boehringer Ingelheim
 - 10.6.1 Boehringer Ingelheim Genetic COPD Basic Information
 - 10.6.2 Boehringer Ingelheim Genetic COPD Product Overview
 - 10.6.3 Boehringer Ingelheim Genetic COPD Product Market Performance
 - 10.6.4 Boehringer Ingelheim Business Overview
 - 10.6.5 Boehringer Ingelheim Recent Developments
- 10.7 Kamada Ltd
 - 10.7.1 Kamada Ltd Genetic COPD Basic Information
 - 10.7.2 Kamada Ltd Genetic COPD Product Overview
 - 10.7.3 Kamada Ltd Genetic COPD Product Market Performance
 - 10.7.4 Kamada Ltd Business Overview
 - 10.7.5 Kamada Ltd Recent Developments
- 10.8 GlaxoSmithKline
 - 10.8.1 GlaxoSmithKline Genetic COPD Basic Information
 - 10.8.2 GlaxoSmithKline Genetic COPD Product Overview
 - 10.8.3 GlaxoSmithKline Genetic COPD Product Market Performance

- 10.8.4 GlaxoSmithKline Business Overview
- 10.8.5 GlaxoSmithKline Recent Developments
- 10.9 CSL Behring
 - 10.9.1 CSL Behring Genetic COPD Basic Information
 - 10.9.2 CSL Behring Genetic COPD Product Overview
 - 10.9.3 CSL Behring Genetic COPD Product Market Performance
 - 10.9.4 CSL Behring Business Overview
 - 10.9.5 CSL Behring Recent Developments
- 10.10 Takeda
 - 10.10.1 Takeda Genetic COPD Basic Information
 - 10.10.2 Takeda Genetic COPD Product Overview
 - 10.10.3 Takeda Genetic COPD Product Market Performance
 - 10.10.4 Takeda Business Overview
 - 10.10.5 Takeda Recent Developments
- 10.11 LFB Biomedicaments
 - 10.11.1 LFB Biomedicaments Genetic COPD Basic Information
 - 10.11.2 LFB Biomedicaments Genetic COPD Product Overview
 - 10.11.3 LFB Biomedicaments Genetic COPD Product Market Performance
 - 10.11.4 LFB Biomedicaments Business Overview
 - 10.11.5 LFB Biomedicaments Recent Developments
- 10.12 Abeona Therapeutics
 - 10.12.1 Abeona Therapeutics Genetic COPD Basic Information
 - 10.12.2 Abeona Therapeutics Genetic COPD Product Overview
 - 10.12.3 Abeona Therapeutics Genetic COPD Product Market Performance
 - 10.12.4 Abeona Therapeutics Business Overview
 - 10.12.5 Abeona Therapeutics Recent Developments
- 10.13 Biogen
 - 10.13.1 Biogen Genetic COPD Basic Information
 - 10.13.2 Biogen Genetic COPD Product Overview
 - 10.13.3 Biogen Genetic COPD Product Market Performance
 - 10.13.4 Biogen Business Overview
 - 10.13.5 Biogen Recent Developments
- 10.14 Vertex Pharmaceuticals
 - 10.14.1 Vertex Pharmaceuticals Genetic COPD Basic Information
 - 10.14.2 Vertex Pharmaceuticals Genetic COPD Product Overview
 - 10.14.3 Vertex Pharmaceuticals Genetic COPD Product Market Performance
 - 10.14.4 Vertex Pharmaceuticals Business Overview
 - 10.14.5 Vertex Pharmaceuticals Recent Developments
- 10.15 Baxalta

- 10.15.1 Baxalta Genetic COPD Basic Information
- 10.15.2 Baxalta Genetic COPD Product Overview
- 10.15.3 Baxalta Genetic COPD Product Market Performance
- 10.15.4 Baxalta Business Overview
- 10.15.5 Baxalta Recent Developments
- 10.16 Arrowhead Research Corporation
 - 10.16.1 Arrowhead Research Corporation Genetic COPD Basic Information
 - 10.16.2 Arrowhead Research Corporation Genetic COPD Product Overview
 - 10.16.3 Arrowhead Research Corporation Genetic COPD Product Market Performance
 - 10.16.4 Arrowhead Research Corporation Business Overview
 - 10.16.5 Arrowhead Research Corporation Recent Developments
- 10.17 ProBioGen
 - 10.17.1 ProBioGen Genetic COPD Basic Information
 - 10.17.2 ProBioGen Genetic COPD Product Overview
 - 10.17.3 ProBioGen Genetic COPD Product Market Performance
 - 10.17.4 ProBioGen Business Overview
 - 10.17.5 ProBioGen Recent Developments
- 10.18 Chiesi Pharmaceuticals
 - 10.18.1 Chiesi Pharmaceuticals Genetic COPD Basic Information
 - 10.18.2 Chiesi Pharmaceuticals Genetic COPD Product Overview
 - 10.18.3 Chiesi Pharmaceuticals Genetic COPD Product Market Performance
 - 10.18.4 Chiesi Pharmaceuticals Business Overview
 - 10.18.5 Chiesi Pharmaceuticals Recent Developments
- 10.19 Kedrion Group
 - 10.19.1 Kedrion Group Genetic COPD Basic Information
 - 10.19.2 Kedrion Group Genetic COPD Product Overview
 - 10.19.3 Kedrion Group Genetic COPD Product Market Performance
 - 10.19.4 Kedrion Group Business Overview
 - 10.19.5 Kedrion Group Recent Developments
- 10.20 ProMetic Life Sciences
 - 10.20.1 ProMetic Life Sciences Genetic COPD Basic Information
 - 10.20.2 ProMetic Life Sciences Genetic COPD Product Overview
 - 10.20.3 ProMetic Life Sciences Genetic COPD Product Market Performance
 - 10.20.4 ProMetic Life Sciences Business Overview
 - 10.20.5 ProMetic Life Sciences Recent Developments

11 GENETIC COPD MARKET FORECAST BY REGION

- 11.1 Global Genetic COPD Market Size Forecast
- 11.2 Global Genetic COPD Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Genetic COPD Market Size Forecast by Country
 - 11.2.3 Asia Pacific Genetic COPD Market Size Forecast by Region
 - 11.2.4 South America Genetic COPD Market Size Forecast by Country
 - 11.2.5 Middle East and Africa Forecasted Sales of Genetic COPD by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

- 12.1 Global Genetic COPD Market Forecast by Type (2025-2032)
 - 12.1.1 Global Forecasted Sales of Genetic COPD by Type (2025-2032)
 - 12.1.2 Global Genetic COPD Market Size Forecast by Type (2025-2032)
 - 12.1.3 Global Forecasted Price of Genetic COPD by Type (2025-2032)
- 12.2 Global Genetic COPD Market Forecast by Application (2025-2032)
 - 12.2.1 Global Genetic COPD Sales (K MT) Forecast by Application
 - 12.2.2 Global Genetic COPD Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

I would like to order

Product name: Global Genetic COPD Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G3D633C43962EN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3D633C43962EN.html>